Medical Xpress October 18, 2023
Nancy Fliesler, Children's Hospital Boston

Today, nearly 900 disorders caused by a single gene are known to be treatable. Yet the recommended “heel stick” testing for newborns only covers about 60 inherited, treatable disorders, and many individual states screen for fewer. What if newborns could instead have their entire genome sequenced at birth, with the results shared and acted on as appropriate?

That was the premise behind the original BabySeq study. That study ran from 2013 to 2019 at the NICU and other ICUs at Boston Children’s Hospital, and at the well-baby unit at Brigham and Women’s Hospital. Of 159 newborns whose families opted to participate, 11% had unanticipated genetic variants associated with disease. All findings were medically actionable, meaning that the child could benefit...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Equity/SDOH, Healthcare System, Patient / Consumer, Pharma / Biotech, Precision Medicine, Provider
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article